IPO Issue Details
Issue Price / Price Band₹61 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size2,000 Shares per Lot
Total Issue Size48,10,000 shares (aggregating up to ₹29.34 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformNSE SME
IPO TypeSME
Subscription OpenWed, 13 Nov 2024
Subscription CloseMon, 18 Nov 2024
Anchor AllotmentTue, 12 Nov 2024
Basis of AllotmentTue, 19 Nov 2024
Initiation of RefundsWed, 20 Nov 2024
Credit of Shares to DematWed, 20 Nov 2024
Listing DateFri, 22 Nov 2024
UPI Mandate Deadline2024-11-18
Application & Investment Details
Retail — Min (1 Lots)₹1,22,000 — 2,000 shares
Retail — Max (13 Lots)₹1,586,000 (13 Lots)
HNI — Min (2 Lots)₹2,44,000 — 4,000 shares
EPS (Pre-IPO)₹2.28
EPS (Post-IPO)₹4.33
P/E Ratio (Pre-IPO)26.81x
P/E Ratio (Post-IPO)14.1x
Net Offer to Public45,66,000 shares (aggregating up to ₹27.85 Cr)
Reserved for Market Maker2,44,000 shares (aggregating up to ₹1.49 Cr)
Pre-IPO Promoter Holding1,33,22,200 shares
Post-IPO Promoter Holding1,81,32,200 shares
About Onyx Biotec Ltd
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.As of July 31, 2024, the company has 175 employees across various departments.
Objects of the Issue
Onyx Biotec Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use
2
Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
3
Prepayment or repayment of all or a portion of certain loans availed by the Company; and
4
General Corporate Purposes.
Shareholding & Lock-in
Pre-IPO Promoter Holding
1,33,22,200 shares
Post-IPO Promoter Holding
1,81,32,200 shares